Atria Investments LLC Myovant Sciences Ltd. Transaction History

Atria Investments LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$6.55 - $14.76 $123,572 - $278,462	-18,866 Reduced 52.67%	16,953 $128,000
Q4 2019 Feb 11, 2020	BUY	$4.2 - $19.21 $150,439 - $688,082	35,819 New	35,819 $556,000
Q3 2019 Nov 14, 2019	SELL	$5.19 - $9.46 $118,928 - $216,775	-22,915 Closed	0 $0
Q2 2019 Aug 26, 2019	BUY	$8.69 - $25.0 $199,131 - $572,875	22,915 New	22,915 $162,000
Q2 2019 Aug 09, 2019	SELL	$8.69 - $25.0 $105,974 - $304,875	-12,195 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$16.83 - $24.45 $205,241 - $298,167	12,195 New	12,195 $291,000
Q4 2018 Feb 12, 2019	SELL	$15.01 - $25.2 $113,790 - $191,041	-7,581 Closed	0 $0
Q3 2018 Oct 09, 2018	BUY	$19.33 - $26.78 $146,540 - $203,019	7,581 New	7,581 $201,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Atria Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Atria Investments LLC with notifications on news.